Indium

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Indium
DrugBank Accession Number
DB11659
Background

Indium has been used in trials studying the basic science of Clear Cell Renal Cell Carcinoma.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 114.818
Monoisotopic: 114.90387878
Chemical Formula
In
Synonyms
  • indio

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Indium AcetateBNM20F6I0P25114-58-3VBXWCGWXDOBUQZ-UHFFFAOYSA-K
Indium Chloride31JB8MKF8Z10025-82-8PSCMQHVBLHHWTO-UHFFFAOYSA-K
Indium CitrateP7RCN32R8Q4194-69-8VSEUCCPAJZHJSX-UHFFFAOYSA-K
Indium NitrateWOP84073FA13770-61-1LKRFCKCBYVZXTC-UHFFFAOYSA-N
Indium Sulfate514CE39CG413464-82-9XGCKLPDYTQRDTR-UHFFFAOYSA-H

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as homogeneous post-transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a post-transition metal atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous post-transition metal compounds
Sub Class
Not Available
Direct Parent
Homogeneous post-transition metal compounds
Alternative Parents
Not Available
Substituents
Homogeneous post-transition metal
Molecular Framework
Not Available
External Descriptors
boron group element atom (CHEBI:30430)
Affected organisms
Not Available

Chemical Identifiers

UNII
045A6V3VFX
CAS number
7440-74-6
InChI Key
APFVFJFRJDLVQX-UHFFFAOYSA-N
InChI
InChI=1S/In
IUPAC Name
indigane
SMILES
[In]

References

General References
Not Available
PubChem Compound
5359967
PubChem Substance
347828029
ChemSpider
4514408
RxNav
1362699
ChEBI
30430
Wikipedia
Indium

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentMalignant Lymphomas1
2SuspendedTreatmentGlioblastoma Multiforme (GBM)1
2TerminatedTreatmentMalignant Lymphomas1
2TerminatedTreatmentMultiple Myeloma (MM)1
2, 3CompletedTreatmentNeuroendocrine Tumours (NETs)1
1Active Not RecruitingBasic ScienceCystic Fibrosis (CF)1
1CompletedDiagnosticNeoplasms, Colonic1
1CompletedTreatmentChronic Myelomonocytic Leukemia (CMML) / Myelodysplastic Syndromes, Previously Treated / Recurrent Acute Myeloid Leukemia, Adult / Recurrent Adult Acute Lymphoblastic Leukemia (ALL) / Refractory Anemia With Excess Blasts / Secondary Acute Myeloid Leukemia (Secondary AML, sAML)1
1RecruitingDiagnosticRenal Cell Adenocarcinoma1
1TerminatedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Angioimmunoblastic T-cell Lymphoma (AITL) / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepato-splenic T-cell Lymphoma / Intraocular Lymphoma / Large Cell Anaplastic Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 20:38 / Updated on June 12, 2020 16:53